Logo image of AADI

AADI BIOSCIENCE INC (AADI) Stock Fundamental Analysis

USA - NASDAQ:AADI - US00032Q1040 - Common Stock

2.05 USD
-0.05 (-2.38%)
Last: 3/18/2025, 8:20:08 PM
2.06 USD
+0.01 (+0.49%)
After Hours: 3/18/2025, 8:20:08 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to AADI. AADI was compared to 534 industry peers in the Biotechnology industry. AADI scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. AADI does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

AADI had negative earnings in the past year.
AADI had a negative operating cash flow in the past year.
In the past 5 years AADI always reported negative net income.
AADI had a negative operating cash flow in each of the past 5 years.
AADI Yearly Net Income VS EBIT VS OCF VS FCFAADI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of -71.98%, AADI is doing worse than 65.44% of the companies in the same industry.
With a Return On Equity value of -89.57%, AADI perfoms like the industry average, outperforming 48.95% of the companies in the same industry.
Industry RankSector Rank
ROA -71.98%
ROE -89.57%
ROIC N/A
ROA(3y)-50.74%
ROA(5y)-44.04%
ROE(3y)-60.48%
ROE(5y)-51.04%
ROIC(3y)N/A
ROIC(5y)N/A
AADI Yearly ROA, ROE, ROICAADI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 5K 10K

1.3 Margins

The Gross Margin of AADI (87.39%) is better than 88.95% of its industry peers.
The Profit Margin and Operating Margin are not available for AADI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 87.39%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AADI Yearly Profit, Operating, Gross MarginsAADI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -2K -4K -6K -8K

More info and screens

6

2. Health

2.1 Basic Checks

AADI does not have a ROIC to compare to the WACC, probably because it is not profitable.
AADI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
AADI Yearly Shares OutstandingAADI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M
AADI Yearly Total Debt VS Total AssetsAADI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -3.05, we must say that AADI is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of AADI (-3.05) is comparable to the rest of the industry.
AADI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.05
ROIC/WACCN/A
WACC10.38%
AADI Yearly LT Debt VS Equity VS FCFAADI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M 150M

2.3 Liquidity

A Current Ratio of 4.89 indicates that AADI has no problem at all paying its short term obligations.
AADI has a Current ratio (4.89) which is in line with its industry peers.
A Quick Ratio of 4.54 indicates that AADI has no problem at all paying its short term obligations.
AADI has a Quick ratio (4.54) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.89
Quick Ratio 4.54
AADI Yearly Current Assets VS Current LiabilitesAADI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 3.69% over the past year.
EPS 1Y (TTM)3.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%14.43%

3.2 Future

AADI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 33.74% yearly.
Based on estimates for the next years, AADI will show a very negative growth in Revenue. The Revenue will decrease by -14.87% on average per year.
EPS Next Y71.14%
EPS Next 2Y23.74%
EPS Next 3Y15.15%
EPS Next 5Y33.74%
Revenue Next Year-46.53%
Revenue Next 2Y-24.02%
Revenue Next 3Y38.79%
Revenue Next 5Y-14.87%

3.3 Evolution

AADI Yearly Revenue VS EstimatesAADI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2020 2021 2022 2023 2024 2025 2026 2027 2031 2032 20M 40M 60M
AADI Yearly EPS VS EstimatesAADI Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AADI. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AADI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AADI Price Earnings VS Forward Price EarningsAADI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AADI Per share dataAADI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

AADI's earnings are expected to grow with 15.15% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.74%
EPS Next 3Y15.15%

More info and screens

0

5. Dividend

5.1 Amount

AADI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AADI BIOSCIENCE INC

NASDAQ:AADI (3/18/2025, 8:20:08 PM)

After market: 2.06 +0.01 (+0.49%)

2.05

-0.05 (-2.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-18 2025-03-18/amc
Earnings (Next)05-06 2025-05-06/bmo
Inst Owners61.01%
Inst Owner Change0%
Ins Owners11.42%
Ins Owner Change0%
Market Cap94.85M
Revenue(TTM)N/A
Net Income(TTM)-61687000
Analysts47.5
Price Target3.06 (49.27%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)12.35%
Min EPS beat(2)1.43%
Max EPS beat(2)23.27%
EPS beat(4)3
Avg EPS beat(4)7.54%
Min EPS beat(4)-3.76%
Max EPS beat(4)23.27%
EPS beat(8)6
Avg EPS beat(8)9.48%
EPS beat(12)9
Avg EPS beat(12)8.71%
EPS beat(16)12
Avg EPS beat(16)6.92%
Revenue beat(2)1
Avg Revenue beat(2)2.47%
Min Revenue beat(2)-2.25%
Max Revenue beat(2)7.19%
Revenue beat(4)1
Avg Revenue beat(4)-3.79%
Min Revenue beat(4)-18.68%
Max Revenue beat(4)7.19%
Revenue beat(8)3
Avg Revenue beat(8)-1.69%
Revenue beat(12)7
Avg Revenue beat(12)204.18%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)10.2%
EPS NY rev (1m)8.11%
EPS NY rev (3m)-7.94%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.68%
Revenue NY rev (1m)0.04%
Revenue NY rev (3m)-1.52%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.78
P/FCF N/A
P/OCF N/A
P/B 1.38
P/tB 1.38
EV/EBITDA N/A
EPS(TTM)-2.35
EYN/A
EPS(NY)-0.68
Fwd EYN/A
FCF(TTM)-1.22
FCFYN/A
OCF(TTM)-1.17
OCFYN/A
SpS0.54
BVpS1.49
TBVpS1.49
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -71.98%
ROE -89.57%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 87.39%
FCFM N/A
ROA(3y)-50.74%
ROA(5y)-44.04%
ROE(3y)-60.48%
ROE(5y)-51.04%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.29
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1232.43%
Cap/Sales 9.09%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.89
Quick Ratio 4.54
Altman-Z -3.05
F-Score3
WACC10.38%
ROIC/WACCN/A
Cap/Depr(3y)890.25%
Cap/Depr(5y)600.82%
Cap/Sales(3y)7.89%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)3.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.67%
EPS Next Y71.14%
EPS Next 2Y23.74%
EPS Next 3Y15.15%
EPS Next 5Y33.74%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%14.43%
Revenue Next Year-46.53%
Revenue Next 2Y-24.02%
Revenue Next 3Y38.79%
Revenue Next 5Y-14.87%
EBIT growth 1Y8.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-10.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-6.68%
OCF growth 3YN/A
OCF growth 5YN/A

AADI BIOSCIENCE INC / AADI FAQ

What is the ChartMill fundamental rating of AADI BIOSCIENCE INC (AADI) stock?

ChartMill assigns a fundamental rating of 2 / 10 to AADI.


Can you provide the valuation status for AADI BIOSCIENCE INC?

ChartMill assigns a valuation rating of 0 / 10 to AADI BIOSCIENCE INC (AADI). This can be considered as Overvalued.


What is the profitability of AADI stock?

AADI BIOSCIENCE INC (AADI) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for AADI stock?

The Earnings per Share (EPS) of AADI BIOSCIENCE INC (AADI) is expected to grow by 71.14% in the next year.


How sustainable is the dividend of AADI BIOSCIENCE INC (AADI) stock?

The dividend rating of AADI BIOSCIENCE INC (AADI) is 0 / 10 and the dividend payout ratio is 0%.